HST5
|
Evaluation title: Eliglustat for treating type 1 Gaucher disease
|
Section
|
Key conclusion
|
Eliglustat is recommended within its marketing authorisation for treating type 1 Gaucher disease, that is, for long-term treatment in adults who are cytochrome P450 2D6 poor, intermediate or extensive metabolisers. Eliglustat is only recommended when the company provides it with the discount agreed in the patient access scheme.
|
1.1
|
The committee concluded that eliglustat is an effective treatment for type 1 Gaucher disease, but remained concerned about the uncertainty of effectiveness in comparison with enzyme replacement therapy (ERT) in the long term.
|
5.8
|
The committee appreciated the important advantages of an oral treatment and, together with its consideration that eliglustat was cost saving compared with ERT, the committee concluded that it could recommend eliglustat.
|
5.21
|
The committee noted that its considerations on the value for money of eliglustat were based on the current evidence and clinical practice, but that they would need to be reconsidered if ERT was no longer available in routine practice.
|
5.10
|
Current practice
|
Nature of the condition, including availability of other treatment options
|
The committee understood that type 1 Gaucher disease is a debilitating condition with symptoms such as fatigue, bone pain and reduced mobility, which have a significant impact on quality of life.
|
5.1
|
ERTs such as velaglucerase alfa and imiglucerase are established and effective treatments available in the NHS, but can be burdensome because they are administered intravenously.
|
5.2
|
The technology
|
Proposed benefits of the technology
How innovative is the technology in its potential to make a significant and substantial impact on health-related benefits?
|
The committee noted that, because eliglustat is an oral therapy, it would give people the freedom to travel and attend university, and remove the need for people to take time off work for intravenous infusion appointments. The committee concluded that eliglustat is likely to have a significant impact on people's lives beyond its direct health benefits.
|
5.19
|
Adverse reactions
|
The committee understood that the adverse effects associated with eliglustat were acceptable to patients, especially in the context of the advantages of oral administration.
|
5.9
|
Clinical evidence
|
Availability, nature and quality of evidence
|
The main evidence for eliglustat came from the ENCORE and ENGAGE trials. The statistical design of the ENCORE trial was to test non-inferiority. There were no trials comparing eliglustat with velaglucerase alfa.
|
4.4
|
The committee noted the evidence review group's (ERG's) comments that the trials were of reasonable quality. It heard from the clinical experts that the populations were generalisable to patients in clinical practice in England.
|
5.3
|
Uncertainties generated by the evidence
|
The committee discussed the following areas of uncertainty:
-
dosages of eliglustat and ERT in the trials compared with dosage in practice
-
the lack of comparative data with ERT for patients who had not had previous treatment
-
the scarce data on patients with poor metaboliser status.
|
5.5, 5.6, 5.7
|
Impact of the technology
|
The committee concluded that eliglustat is an effective treatment for type 1 Gaucher disease, but remained concerned about the uncertainty of effectiveness in comparison with ERT in the long term.
|
5.8
|
Cost evidence
|
Availability and nature of evidence
|
The company submitted a cost–consequence model comparing eliglustat with imiglucerase and with velaglucerase alfa in 2 patient populations: those who were treatment naive and those who were taking ERT and whose disease was considered clinically stable. The semi-Markov model included 10 health states.
|
4.28
|
The company presented a 5‑year budget impact analysis to estimate the costs of eliglustat to the NHS.
|
4.39
|
Uncertainties around and plausibility of assumptions and inputs in the economic model and budget impact analysis
|
Cost–consequence analysis
The committee considered that there was uncertainty around the assumption of equivalence of eliglustat with ERT in the long term.
The dose of ERT in the company's analysis was higher than that used in clinical practice.
The committee considered that:
-
the company's assumption that mortality risk does not increase with disease severity was unrealistic
-
administration costs for ERT were likely to be overestimated in the company's model because they were higher than the costs of hospital administration
-
assuming no administration costs for eliglustat was unrealistic
-
the utility increment (0.12) assumed for oral treatment was too high and the true value was uncertain, but the alternative value (0.05) used by the ERG was more appropriate.
|
5.10, 5.11
|
Budget impact model
The company's analysis was based on estimates of total costs generated by the cost–consequence model, so uncertainties in the model carried through. The committee concluded that company's estimates of budget impact were additionally uncertain because:
-
the model excluded poor metabolisers
-
the dosage of ERT was assumed to be higher than in clinical practice
-
of incorporation of mortality and stopping treatment in estimated total costs.
The committee considered the ERG's exploratory analyses around the assumptions made by the company to be more plausible.
|
5.17, 5.18
|
Incorporation of health-related quality-of-life benefits and utility values
Have any potential significant and substantial health-related benefits been identified that were not included in the economic model, and how have they been considered?
|
The committee noted the ERG's comments that a utility increment of 0.12 (assumed by the company) was substantial when compared with the decrements from significant adverse events and the benefits of other oral therapies estimated in previous NICE submissions
The committee concluded that, although the true value was uncertain, the alternative value (0.05) used by the ERG was more appropriate.
|
5.11
|
Cost to the NHS and PSS
|
Based on the ERG's exploratory analyses, and taking into account the confidential discounts available for eliglustat and ERT, eliglustat resulted in cost savings compared with ERT.
|
5.18
|
Value for money
|
Based on the ERG's exploratory analyses, and taking into account the confidential discounts available for eliglustat and ERT, eliglustat resulted in cost savings compared with ERT across the populations.
|
5.7
|
The committee was mindful of the uncertainty around the long-term impact of eliglustat but appreciated the important advantages of an oral treatment. The committee concluded that, taking into the confidential discounts for ERT and eliglustat, eliglustat offered value for money compared with ERT.
|
5.13, 5.14
|
Impact beyond direct health benefits and on the delivery of the specialised service
|
The committee concluded that eliglustat is likely to have a significant impact on people's lives beyond its direct health benefits because it is an oral therapy.
|
5.19
|
Additional factors taken into account
|
Equalities considerations and social value judgements
|
No equality issues that needed to be taken into consideration by the committee were identified.
|
–
|